Rifamycin Treatment of Tuberculosis in a Patient Receiving Atenolol: Less Interaction with Rifabutin than with Rifampin

Goldberg, Stefan V.; Hanson, Daniel; Peloquin, Charles A.
August 2003
Clinical Infectious Diseases;8/15/2003, Vol. 37 Issue 4, p607
Academic Journal
Comments on an article about the substitution of rifabutin for rifampin in the treatment of patients with tuberculosis who develop intolerable rifampin side effects. Reduction of blood concentrations of many classes of medications that are metabolized in the liver, by rifampin; Illustrative case.


Related Articles

  • Caspofungin/rifampicin interaction.  // Reactions Weekly;10/6/2012, Issue 1422, p15 

    The article describes the case of a 65-year-old woman who developed Candida (C.) parapsilosis candidaemia due to failure of treatment with caspofungin for C. lusitaniae while receiving rifampicin for Mycobacterium tuberculosis.

  • Coma and brain stem areflexia in brain stem encephalitis (Fisher's syndrome). Al-Din, A S; Jamil, A S; Shakir, R // British Medical Journal (Clinical Research Edition);Aug1985, Vol. 291 Issue 6494, p535 

    No abstract available.

  • Treatment of tuberculosis. Cooke, Nigel J. // British Medical Journal (Clinical Research Edition);8/24/1985, Vol. 291 Issue 6495, p497 

    Focuses on the treatment of tuberculosis in Great Britain. Discovery of rifampicin and ethambutol; Re-appraisal of pyrazinamide; Discussion on the difficulty of changing doctors' prescribing habits in tuberculosis.

  • The totally drug resistant tuberculosis (TDR-TB). Velayati, Ali Akbar; Farnia, Parissa; Masjedi, Mohammad Reza // International Journal of Clinical & Experimental Medicine;2013, Vol. 6 Issue 4, p307 

    A letter to the editor is presented which discusses totally drug-resistant tuberculosis (TDR-TB) for TB strains which showed in-vitro resistance to all first and second line drugs tested including isoniazid, rifampicin, and cycloserine.

  • Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. Helen McIlleron; Jennifer Norman; Thomas P. Kanyok; P. Bernard Fourie; John Horton; Peter J. Smith // Journal of Antimicrobial Chemotherapy (JAC);Dec2007, Vol. 60 Issue 6, p1398 

    Objectives Pharmacokinetic drug–drug interactions were investigated between the fluoroquinolone gatifloxacin and a fixed dose combination (FDC) of rifampicin, isoniazid and pyrazinamide. Patients and methods The single-dose pharmacokinetics of the four drugs was evaluated in an...

  • Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis Treatment. van Hest, Rob; Baars, Hennie; Kik, Sandra; van Gerven, Paul; Trompenaars, Marie-Christine; Kalisvaart, Nico; Keizer, Sytze; Borgdorff, Martien; Mensen, Marlies; Cobelens, Frank // Clinical Infectious Diseases;8/15/2004, Vol. 39 Issue 4, p488 

    Background. Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide. Methods. A retrospective cohort study in The Netherlands compared the hepatotoxicity of preventive treatment with rifampin-pyrazinamide...

  • Rifampicin: Acute kidney injury: case report.  // Reactions Weekly;Dec2013, Issue 1481, p30 

    The article presents a case study of a 47-year-old man who suffered from acute kidney injury during treatment with rifampicin for pulmonary tuberculosis.

  • Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa. Rabna, Paulo; Ramos, Jorge; Ponce, Gema; Sanca, Lilica; Mané, Morto; Armada, Ana; Machado, Diana; Vieira, Fina; Gomes, Victor F.; Martins, Elisabete; Colombatti, Raffaella; Riccardi, Fabio; Perdigão, João; Sotero, Joana; Portugal, Isabel; Couto, Isabel; Atouguia, Jorge; Rodrigues, Amabélia; Viveiros, Miguel // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: This study aimed to evaluate the usefulness of the Xpert MTB/RIF assay for the rapid direct detection of M. tuberculosis complex (MTBC) strains and rifampicin resistance associated mutations in a resource-limited setting such as Guinea-Bissau and its implications in the management...

  • Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Anne Aspler // Thorax;Jul2010, Vol. 65 Issue 7, p582 

    RATIONALE: Treatment for latent tuberculosis infection with isoniazid for 9 months (9INH) has poor completion and serious adverse events, while treatment for 4 months with daily rifampin (4RIF) has significantly higher completion and fewer adverse events. OBJECTIVES: To compare the health...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics